Randomized controlled multicentre study comparing biological mesh closure of the pelvic floor with primary perineal wound closure after extralevator abdominoperineal resection for rectal cancer (BIOPEX-study) by Musters, G.D. (Gijsbert) et al.
Musters et al. BMC Surgery 2014, 14:58
http://www.biomedcentral.com/1471-2482/14/58STUDY PROTOCOL Open AccessRandomized controlled multicentre study
comparing biological mesh closure of the pelvic
floor with primary perineal wound closure after
extralevator abdominoperineal resection for rectal
cancer (BIOPEX-study)
Gijsbert D Musters1, Willem A Bemelman1, Robbert JI Bosker2, Jacobus WA Burger3, Peter van Duijvendijk4,
Boudewijn van Etten5, Anna AW van Geloven6, Eelco JR de Graaf7, Christiaan Hoff8, Niels de Korte9,
Jeroen WA Leijtens10, Harm JT Rutten11, Baljit Singh12, Anthony van de Ven13, Ronald JCLM Vuylsteke14,
Johannes HW de wilt15, Marcel GW Dijkgraaf16 and Pieter J Tanis1*Abstract
Background: Primary perineal wound closure after conventional abdominoperineal resection (cAPR) for rectal
cancer has been the standard of care for many years. Since the introduction of neo-adjuvant radiotherapy and the
extralevator APR (eAPR), oncological outcome has been improved, but at the cost of increased rates of perineal
wound healing problems and perineal hernia. This has progressively increased the use of biological meshes,
although not supported by sufficient evidence. The aim of this study is to determine the effectiveness of pelvic
floor reconstruction using a biological mesh after standardized eAPR with neo-adjuvant (chemo)radiotherapy
compared to primary perineal wound closure.
Methods/Design: In this multicentre randomized controlled trial, patients with a clinical diagnosis of primary
rectal cancer who are scheduled for eAPR after neo-adjuvant (chemo)radiotherapy will be considered eligible.
Exclusion criteria are prior radiotherapy, sacral resection above S4/S5, allergy to pig products or polysorbate,
collagen disorders, and severe systemic diseases affecting wound healing, except for diabetes. After informed
consent, 104 patients will be randomized between standard care using primary wound closure of the perineum
and the experimental arm consisting of suturing a biological mesh derived from porcine dermis in the pelvic
floor defect, followed by perineal closure similar to the control arm. Patients will be followed for one year after the
intervention and outcome assessors and patients will be blinded for the study treatment. The primary endpoint is
the percentage of uncomplicated perineal wound healing, defined as a Southampton wound score of less than II
on day 30. Secondary endpoints are hospital stay, incidence of perineal hernia, quality of life, and costs.
Discussion: The BIOPEX-study is the first randomized controlled multicentre study to determine the additive value
of using a biological mesh for perineal wound closure after eAPR with neo-adjuvant radiotherapy compared to
primary perineal wound closure with regard to perineal wound healing and the occurrence of perineal hernia.
Trail registration number: NCT01927497 (Clinicaltrial.gov).
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Conventional abdominoperineal resection (cAPR) for
distal rectal cancer is associated with relatively high rates
of positive resection margins and iatrogenic tumour
perforation. Pooled analysis of five European randomized
controlled trials revealed that cAPR was an independent
risk factor for local recurrence (19.7% versus 11.4%) and
associated with a decreased 5-year survival rate (59% versus
70%) compared to low anterior resection [1]. Following the
total mesorectal excision (TME) plane all the way down to
the pelvic floor, as performed in cAPR, results in the typical
coning of the specimen and thereby compromising
resection margins. Extralevator APR (eAPR) reduces the
rate of positive resection margins and tumour perforation
and improves oncological outcome based on a systematic
review of non-randomized studies [2]. The extralevator
approach entails en bloc resection of the distal rectum,
sphincter complex and levator muscles. Besides a change
in surgical technique, neo-adjuvant radiotherapy has also
contributed to better locoregional control in patients with
distal rectal cancer.
Both wider excisions as a result of eAPR as well as
increased use of neo-adjuvant (chemo)radiotherapy have
significantly increased perineal wound healing problems,
which have been reported in up to 59% [3-6]. Furthermore,
perineal hernia is more likely to occur with a reported
incidence of up to 20% [7]. Perineal wound complications
may only consist of superficial infection or minor dehiscence,
but are often more serious with major dehiscence or deep
abscesses. Impaired perineal wound healing is a significant
clinical problem being associated with increased hospital
stay, the need for re-operation, and intensive wound care for
several months. There is even a small proportion of patients
in whom a presacral or perineal sinus remains. Quality of
life may be severely impaired because of pain, smelly
wound discharge, and interference with basic daily activities
such as sitting and walking.
Internationally there is a trend towards the use of
additional closure techniques after eAPR in an attempt to
overcome this clinical problem. One of these techniques is
the reconstruction of the pelvic floor with a biological
mesh, but available literature data are scarce. A recently
published review included 12 studies, of which six were
only conference abstracts, with total numbers of included
patients between 2 and 24 [8]. The percentage of minor
wound complications in series with at least 5 patients
ranged between 17% and 63%, and of major complications
between 9% and 27%. Two larger studies not included in
this review reported a perineal wound complication rate
of 50% and 11% in 30 and 35 patients respectively [9,10].
Autologous tissue flaps might also be an option and seems
to be equally effective as a biological mesh [11]. However,
the routine use of flaps after eAPR for rectal cancer
is controversial. The rectus abdominis muscle (RAM)flap cannot be combined with a laparoscopic approach,
will add donor site morbidity, substantially increases
operating time and often implicates assistance by a
plastic surgeon [12]. The gluteal flap does not disturb
abdominal wall integrity, but seems not to prevent
perineal hernia formation [7].
The popularity of the use of biological meshes for
eAPR is probably the result of its successful application
in repair of complex and infected hernias of the abdominal
wall as well as for example pelvic organ prolapses [13,14].
However, the costs of a biological mesh ranges between
500 and 1800 euro per patient depending on the size of
acellular porcine collagen implant and company. Based on
the limited available data and costs of biological meshes,
primary perineal wound closure after eAPR still remains
the standard of care in many institutes. An unpublished
survey among Dutch surgeons performed in 2012 revealed
that 66% exclusively used primary perineal wound closure
after APR, although the extralevator approach is not yet
completely implemented at a national level. Using simple
direct closure of the perineal wound after eAPR is
supported by data from relatively large cohort series
(104 to 282 patients), which reported perineal wound
complication rates between 17% and 35%, with a proportion
of patients who received radiotherapy between 31%
and 60% [5,15-17]. However, standardized perineal
wound assessment was not used in any of these studies and
complication rates may be underestimated because perineal
wound healing was not a primary outcome parameter.
This underlines the need for a randomized comparison of
different perineal closure techniques after eAPR.Methods/Design
Objective
The primary objective of this study is to determine
the effectiveness of pelvic floor reconstruction using a
biological mesh after eAPR with neo-adjuvant radiotherapy
compared to primary perineal closure. It is hypothesized
that biological mesh closure is superior to primary perineal
closure in a cost-effective manner in terms of a higher
primary perineal wound healing rate and a lower perineal
hernia rate at reduced costs.Design
This is a multicentre, single blinded, randomized
controlled trial, in which eligible patients will be
randomized between pelvic floor reconstruction using a
biological mesh (intervention arm) and primary closure of
the perineal defect (standard arm) in a 1:1 ratio (Figure 1).
Randomisation will be performed pre-operatively by a
central automated randomisation using the trial website,
with stratification for age, sex and laparoscopic surgery.
The allocation of treatment is blinded to the patient.
Figure 1 Flow-diagram. eAPR: abdominal perineal resection.
Musters et al. BMC Surgery 2014, 14:58 Page 3 of 7
http://www.biomedcentral.com/1471-2482/14/58The trial will be conducted in five academic centres and
eight teaching hospitals, including two national referral
centres for locally advanced rectal cancer. Participating
centres will perform standardized perineal dissection
according to the extralevator approach. The procedures in
the experimental arm in centres without experience in
biological mesh reconstruction of the pelvic floor will be
supervised by one of the principal investigators (PT and
WB) until a standardized biological mesh placement is
ensured. Furthermore, a preceding investigators’ meeting
will be organized at the start of the trial and a refreshment
course during the inclusion period, both including a
workshop using fresh frozen cadavers. The perineal wound
healing will be evaluated at 7 and 30 days postoperatively
using the Southampton wound scoring system by an inde-
pendent nurse or physician not aware of the intervention to
which the patient was allocated [18]. In addition, full colour
photographs will be taken from the perineal wound and
assessed by an expert panel (PT, WB) blinded for
treatment allocation. During routine outpatient clinicvisits for oncological follow-up at 3, 6, 9 and 12 months,
the perineal wound will be inspected and scored accord-
ingly with respect to healing and herniation (see Figure 1).
In addition, CT-scan of the pelvis as usually performed dur-
ing oncological follow-up at 1 year, will be reviewed with
respect to presacral or perineal sinuses and perineal hernia-
tion. Quality of Life questionnaires will be administered to
the patient at each follow-up interval. Patients without pri-
mary perineal wound healing who are treated in a non-
hospital setting will get a wound diary in which the number
of wound dressing changes, the number of visits by a home
care nurse if applicable, and the wound materials used are
registered per week until final closure of the perineal
wound or end of study period. In addition, the nature and
severity of any wound event, all medical or surgical inter-
ventions and re-admissions will be collected.
Study population
Patients are eligible for this study when they meet the
following inclusion criteria: age of 18 years or older,
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(chemo)radiotherapy, life expectancy of more than
2 years, ability to return for all scheduled and required
study visits, and written informed consent for study
participation. Exclusion criteria are: previous pelvic
irradiation for other cancers (i.e. prostate cancer), total
pelvic exenteration or sacral resection above level S4/S5,
sensitivity to porcine derived products or polysorbate,
severe systemic diseases abibuffecting wound healing
except diabetes (i.e. renal failure requiring dialysis, liver
cirrhosis, and immune compromised status like HIV),
collagen disorders (i.e. Marfan), enrolment in trials with
overlapping primary endpoint or otherwise expected
influence on wound healing (i.e. systemic therapy like
anti-angiogenic agents). An interim review will be per-
formed at 50 included patients (of the total of 104 patients).
At 6 weeks after inclusion of these patients, the trial’s safety
data will be evaluated. The steering committee will be
supplied with the number of (serious) adverse events
in both groups at this time point. If there is a skewed
distribution of the number of (serious) adverse events
between the two groups, an efficacy analysis can be
performed at the discretion of the steering committee.
Following these interim analyses, the steering committee
will advise upon continuation of the trial.
Intervention strategies
The perineal phase of the APR will be performed
according to the principles of an extralevator approach,
which means that the levator muscles will be laterally
transected in order to leave a muscular cuff around the
tumour. The coccyx will not be routinely resected, but
only if indicated based on surgical exposure or oncological
principles. The extent of excision of perineal skin and
ischioanal fat will be as limited as oncologically justified.
The eAPR specimens will be classified according to Phil
Quirke and photographed in a standardized fashion.
Patient positioning (prone or supine), the surgical approach
for the abdominal phase (open or laparoscopic), and the
use of an omental plasty are left to the discretion of the
operating surgeon, because there is no conclusive evidence
on which of these technical aspects is the most optimal
with regard to perineal wound healing.
Closure of the perineum in the control arm consists
of stitching the ischioanal and subcutaneous fat using
interrupted Vicryl sutures in one or two layers. Subse-
quently, the skin will be closed using interrupted sutures
according to the preference of the surgeon. Placement of a
transabdominal or transperineal drain will be performed
according to local protocols.
The intervention in the experimental arm consists of
suturing an acellular biological mesh derived from porcine
dermis in the pelvic floor defect (Strattice™, 6x10 cm). The
mesh will be sutured at each side of the coccyx or distalsacrum with Prolene or Polydioxanone sutures (PDS).
Laterally, the mesh is attached to the remaining of the
levator complex and, anteriorly, to the transverse perineal
muscle. A suction drain will be inserted and positioned on
top of the mesh. The perineal subcutaneous fat and skin
will be subsequently closed in layers similar to primary
perineal closure as performed in the standard arm.
Outcome parameters
Primary endpoint is the percentage of uncomplicated
perineal wound healing defined as a Southampton wound
score less than II at 30 days postoperatively.
Secondary endpoints of this study are the need for
wound care, either in hospital or out of hospital and
specified to frequency, duration, and type of wound dress-
ing, the need for surgical re-intervention or re-admission
for perineal wound problems, total hospital stay during
one year of follow-up, incidence of asymptomatic and
symptomatic perineal hernia, quality of life (EQ-5D-5 L,
EORTC-30, EORTC-29RC, SF-36), and (in)direct medical
and non-medical costs (clinical report forms, hospital
information systems, modified health and labour question-
naire). In addition, perineal wound healing according to the
Southampton wound grading will be repeated at 3, 6,
9 and 12 months postoperatively in order to determine
differences in wound healing between the study arms over
time. Differences in the incidence of persistent perineal or
presacral sinuses, both clinically and by CT imaging, will
be evaluated at 1 year of follow-up.
Sample size calculation
The principal analysis will consist of an intention-to-treat
comparison of the proportions of patients with primary
uncomplicated perineal wound healing between both
study arms. The hypothesis is to test superiority of the
biological mesh assisted closure over primary closure of
the perineum. The currently available literature is difficult
to interpret with regard to perineal wound healing for the
two interventions to be studied, hampering defining the
expected difference in healing rate. Data on primary
closure are mostly derived from cohort series in
which patients were mostly operated upon before
2005 [3-7,10,19-23]. At that time, eAPR was only applied
in a minority of centres. Furthermore, there has been an
enormous increase in the use of neo-adjuvant radiotherapy
in the past decade. These two developments in the
treatment of distal rectal cancer have had a significant
impact on perineal healing rate. In contrast, literature
on biological mesh assisted perineal closure has been
published recently only in patients undergoing eAPR
and with high rates of neo-adjuvant radiotherapy
[7,9,10,20-23]. In addition, these studies had a specific
focus on perineal wound healing, which results in more
detailed data with a relative over-reporting of perineal
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primary closure in which perineal healing was most often
a secondary endpoint that was retrospectively studied.
Both the low percentage of eAPR in the primary closure
group and relative over-reporting of perineal wound
complications in the biological mesh led us to conclude
that the available literature may underestimate the potential
difference between both closure techniques.
Given the before mentioned lack of high quality data in
the literature, we defined a clinically relevant difference in
primary uncomplicated perineal healing which justifies the
routine use of an expensive biological implant. This differ-
ence is considered to be 25%. A total number of 98
patients (49 per group) are needed to be able to detect a
25% increase in primary perineal wound healing by
insertion of a biological mesh from 60% to 85%, applying a
Chi2-test with a two-sided 0.05 significance level and with
80% power. With an estimated drop-out of 5%, a total
number of 104 patients are required (52 per group).
Data-analysis
The primary endpoint, the percentage of uncomplicated
wound healing defined as a Southampton wound score of
less than II at 30 days postoperatively, will be compared
between the two study groups using a two-sided
Chi-square test with a significance level of 0.05. The
primary endpoint will be further explored by comparing
wound scores as categorical variable using the Mann
Whitney U test. Furthermore, differences in time to
healing between the two groups will be analysed as a
censored continuous variable using Kaplan-Meier survival
analysis. Treatment effects will be expressed as a relative
risk with 95% confidence interval. Any binary secondary
outcome measures (e.g. hernia rate, re-operation rate,
infection rates, etc.) will be analysed in the same way as
the primary outcome. Quality of life data (e.g. EQ-5D-5 L,
EORTC-30, EORTC-29RC, SF-36) will be graphically
represented across all time points and analysed using a
repeated measures analysis of variance. The scoring
profiles from a patient on subsequent EQ-5D-5 L assess-
ments up to month 12 will further be used to derive
health utilities based on the most recent crosswalk value
sets at the time of analysis [24]. The health utilities will
then be used to calculate quality adjusted life years
(QALY) as the product sum of the utilities and the lengths
of time preceding the repeated measurements.
The most recent Dutch guideline for costing in health
care research will be applied to assign unit costs to
observed health care resources in order to estimate the
costs of care for each study group [25]. Costs differences
will be off-set against the difference in numbers of
patients with uncomplicated perineal wound healing.
Cost differences will also be off-set against the difference
in quality adjusted life years to calculate the extra costs perQALY gained. Both economic analyses will be performed
from a societal perspective, with a time horizon set at
12 months. In addition, the analyses will be repeated from
a hospital care provider perspective to improve the study’s
generalizability to countries with other health care systems.
No discounting of effects and costs will be performed.
Sensitivity analyses will be performed to account for
sampling variability and key study parameters (unit costs
of the closure procedure using the biological mesh,
alternative utility weights of observed health states).
Results will be displayed graphically with cost-effectiveness
planes and acceptability curves.
Ethics and safety
The medical ethical committee of the Academic Medical
Centre, Amsterdam, the Netherlands, has approved the
study protocol (MEC 2012–360, NL42094.018.12). This
study will be conducted according to the principles of
Good Clinical Practice.
Discussion
The BIOPEX study is the first randomized controlled trial
comparing a new perineal closure technique after eAPR
with primary perineal closure. There is one other registered
ongoing trial on perineal closure after eAPR, but not
including a study arm consisting of what we consider to be
the standard of care, namely primary wound closure. This
is a Swedish study randomizing between gluteus maximus
myocutaneous flap and acellular porcine collagen implant
(NEAPE; trials.gov identifier NCT01347697). Pelvic floor
reconstruction using a musculocutaneous flap such as the
RAM flap is often indicated in large irradiated perineal
defects, for example after salvage surgery for residual or
recurrent anal cancer [26-28]. But routinely using a muscu-
locutaneous flap for perineal reconstruction after APR for
rectal cancer, except for exenterative procedures, seems to
be over-treatment [12]. The gluteal flap as used in the
Swedish trial does not disturb abdominal wall integrity, but
seems not so attractive by significantly increasing surgical
trauma in the irradiated perineum with postoperative
mobilisation problems. If the gluteal flap is used as a
fasciocutaneous flap, it is associated with an unacceptably
high rate of perineal hernia development according to
Christensen et al. [7]. The biological mesh has been
recently introduced and appears to be a valid alternative for
the autologous tissue flaps [7,9,10,19-23]. Since the perineal
wound is by definition contaminated, a biological mesh,
being more resistant to infection, is preferred over less
expensive synthetic meshes. Clinical outcome of a biological
mesh appeared to be comparable to flap assisted perineal
closure in a non-randomized comparison based on system-
atic review of the literature [11]. Furthermore, a biological
mesh is associated with lower costs per patient compared
to a RAM flap [21]. Others have suggested an omental
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filling of dead space rather than giving strength to a neo-
pelvic floor. A biological mesh differs essentially from a
tissue flap by not filling the pelvic defect. Combining an
omental plasty with a biological mesh may therefore be of
additive value. Although a high level of evidence is lacking,
an omental plasty is recommended after APR, because it
adds well vascularised, non-irradiated tissue to the pelvic
cavity [16]. Omental plasty is not routine care in some of
the participating centres of the BIOPEX study, which is the
reason that we decided not to include this into the study
protocol as a required part of the reconstruction.
The costs associated with routinely adding a biological
mesh to the surgical procedure is supposed to ultimately
translate into cost saving by reducing hospital stay, redu-
cing the need for operative reintervention, reducing the
need for intensive wound care and reducing costs related to
secondary repair of perineal hernia. There is even a sub-
group of patients with a persisting perineal sinus after one
year that is unlikely to heal eventually [29]. Non-healing at
one year after pre-operative radiotherapy has been reported
in up to 26% and may also be reduced by biological mesh
assisted closure [19]. The percentage of surgical reinterven-
tion for perineal complications is reported between 8% and
16% and is expected to be halved from 10% to 5% by the
use of a biological mesh [3,19,26]. Furthermore, it is
expected that perineal hernia incidence will be reduced by
at least 10%, based on a difference of 20% as recently
published by Christensen et al. [7]. Although this was a
comparison between gluteal flap and biological mesh,
gluteal flap is similar to primary closure regarding risk of
perineal hernia because it does not reconstruct the pelvic
floor. Primary use of a biological mesh is therefore expected
to reduce by more than half the costs related to secondary
perineal hernia repair requiring hospital admittance for
about three days with operative intervention.
In conclusion, pelvic floor reconstruction using biological
meshes has been suggested to improve perineal wound
healing and may potentially save net health care costs
compared to simple primary closure of the perineum
after eAPR, but proof of which is urgently needed.
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